FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

Phase 3

Completed

Conditions: VZV Infection After Bone Marrow Transplantation

First Posted Date: 2005-09-21

Last Posted Date: 2007-12-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00209352

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon

Phase 2

Completed

Conditions: HIV-1 and HSV-2 Coinfection
HIV Infections

Interventions: Drug: Acyclovir

First Posted Date: 2005-09-21

Last Posted Date: 2011-12-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00209313

Locations: 🇨🇲
Hospital Central, Yaounde, Cameroon

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Phase 2

Completed

Conditions: Stage II Multiple Myeloma
Stage I Multiple Myeloma
Stage III Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: clarithromycin
Drug: thalidomide
Drug: dexamethasone

First Posted Date: 2005-09-16

Last Posted Date: 2017-06-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00182663

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor

Phase 1

Completed

Conditions: Anemia, Aplastic

First Posted Date: 2005-09-05

Last Posted Date: 2008-04-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 85

Registration Number: NCT00144729

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington, United States

Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Quality of Life

First Posted Date: 2005-08-04

Last Posted Date: 2013-05-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 750

Registration Number: NCT00126477

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Effects of Garlic Supplements on Drug Metabolism

Completed

Conditions: Healthy

First Posted Date: 2005-07-22

Last Posted Date: 2010-01-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00122889

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response

Phase 1

Completed

Conditions: Psychological Stress

First Posted Date: 2005-07-21

Last Posted Date: 2012-03-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 126

Registration Number: NCT00121160

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Promoting Activity and Changes in Eating (PACE) to Reduce Obesity

Not Applicable

Completed

Conditions: Obesity
Cardiovascular Diseases
Heart Diseases

Interventions: Behavioral: Diet
Behavioral: Exercise
Behavioral: Environment

First Posted Date: 2005-07-14

Last Posted Date: 2012-08-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3000

Registration Number: NCT00119782

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2

Terminated

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Chronic Myelomonocytic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts in Transformation
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Myelodysplastic Syndromes
Recurrent Childhood Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Radiation: iodine I 131 monoclonal antibody BC8
Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2005-07-13

Last Posted Date: 2022-12-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00119366

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma
B-cell Chronic Lymphocytic Leukemia
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Biological: rituximab
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Radiation: yttrium Y 90 ibritumomab tiuxetan
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2005-07-13

Last Posted Date: 2018-06-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 42

Registration Number: NCT00119392

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy